Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow - Wikidata - awgldk - TriplyDB

Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow

Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow

http://www.wikidata.org/entity/Q33947287

about

Targeting innate immunity for neurodegenerative disorders of the central nervous system Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.Suppressed retinal degeneration in aged wild type and APPswe/PS1ΔE9 mice by bone marrow transplantation Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Aβ42 phagocytosis.How to get from here to there: macrophage recruitment in Alzheimer's disease Apolipoprotein E isoform-dependent microglia migration Expression of mutant alpha-synuclein modulates microglial phenotype in vitro Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal cyclooxygenase-2 function, lipid peroxidation, and neuroprotection.Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus Ecology of the aging human brain Inhibition of STAT3- and MAPK-dependent PGE2 synthesis ameliorates phagocytosis of fibrillar β-amyloid peptide (1-42) via EP2 receptor in EMF-stimulated N9 microglial cells.Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease.Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies Perivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantation Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice.Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease.Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia.Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE2 Signaling in Alzheimer's Disease.Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer's Disease Utilization of APPswe/PS1dE9 Transgenic Mice in Research of Alzheimer's Disease: Focus on Gene Therapy and Cell-Based Therapy Applications.Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where.Friend or Foe? Resident Microglia vs Bone Marrow-Derived Microglia and Their Roles in the Retinal Degeneration.Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease Animal Models of Alzheimer's Disease: Utilization of Transgenic Alzheimer's Disease Models in Studies of Amyloid Beta Clearance.Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice.Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease.Optical Coherence Tomography in Alzheimer's Disease and Other Neurodegenerative Diseases.Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex.

P2860

Q26744219-212CC3BC-6EA0-464D-8586-1266495376C6 Q28552971-2D9F16FD-E184-4C8E-B9F1-E38BAEB3C298 Q30634663-17B54DE6-B5EC-4F13-BD49-CFFDA3334A76 Q34764098-B1BF0948-64CE-4188-A6B3-85DE7117DD1F Q34780834-E2D41A09-0436-4F76-BF75-1E54F67EB3BF Q34912085-FF73F02C-E905-4015-9795-82C7046E8EF5 Q35003241-BC0CD4EE-E446-4F90-9F1E-CF736C09CA5D Q35014520-2EFAF96F-78E8-4DA5-9689-5F70ED9DB9E5 Q35127516-A148E4D2-6B71-4725-B554-915CEF604B94 Q35393742-A574B6A2-F396-4F87-B96F-672202ED189A Q35534894-09DC5740-15D7-4B62-AEBD-F9CB81B8765D Q35556875-463C1A1E-AE63-49E4-BEEC-7F60537B8C86 Q36200280-F49AFEDD-2702-48FE-94D0-933EF16652ED Q36431280-15652F0B-D579-43F7-A73C-DF70852B5705 Q36819400-4036EE6F-DC00-40E6-B5BB-0D176177EF59 Q36997172-CE7A299F-E1F9-41AA-9EF4-55BC9AB4B1C2 Q37081974-82497E08-A03A-4418-AE12-4240F57C6A53 Q37190465-8F26ED3E-3894-4015-B808-4171D2E4E01C Q37208507-03028916-E0E7-4FA5-9337-AAC777C1BD31 Q37588183-474BFD2A-8240-4C8C-89A4-0EA84BDA913C Q37678539-7793BDC3-2D0A-4D74-A422-6D8A14775D93 Q37741526-19FFA481-781E-4F87-9025-9375A1FEB0E2 Q37960498-0DD1D39B-3174-4982-9640-66E7E5F488F6 Q38021993-06FA13C1-2717-48BE-A099-FF4CB1148476 Q38851309-FB6C9355-C68B-4309-BAE0-1B5B1D26F991 Q39135845-8BD0B481-E5CD-4210-8B30-04CB4B0491F1 Q41866014-962F9FA4-BDD5-400E-ABF3-D53CF145F054 Q42119910-AE1D668D-6F0E-4844-A359-74316DE7AEB8 Q42642970-B705F201-7290-4D80-BB3D-7485071246CC Q43224814-E354313B-B6B6-4CE2-AFB9-E2CF0E4D7083 Q47221811-04A824C0-C899-4AEF-9411-895401CC4FE8 Q47332404-99E9626F-45DB-4447-B26D-0C8F6A4E2DA4

P2860

Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow

http://www.wikidata.org/entity/Q33947287

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Suppressed accumulation of cer ...... tor subtype 2-null bone marrow

@ast

Suppressed accumulation of cer ...... tor subtype 2-null bone marrow

@en

type

label

Suppressed accumulation of cer ...... tor subtype 2-null bone marrow

@ast

Suppressed accumulation of cer ...... tor subtype 2-null bone marrow

@en

prefLabel

Suppressed accumulation of cer ...... tor subtype 2-null bone marrow

@ast

Suppressed accumulation of cer ...... tor subtype 2-null bone marrow

@en

P1433

Q33947287-574DB238-7915-4177-AA3F-1E5ADA772445

P1476

Q33947287-388BA3E1-9380-47DE-BE87-A2A063BDF472

P2093

Q33947287-04A1275C-78BC-473B-8F3E-1230A6B658E3

Q33947287-29059BAA-F110-4886-9554-3A76442FC9DA

Q33947287-35AD825E-9C88-4D2B-9C65-1CC0EE233337

Q33947287-512C0724-6AE8-4516-A212-FB7A79C253AC

Q33947287-7CC869A1-85AB-446B-8A73-DE80A7D4BC2F

Q33947287-90DA3492-EEF2-4624-83A0-CD33F893147D

Q33947287-AE81DA93-05D0-40CB-8B14-B168CBB54168

Q33947287-BDCCBC65-6CDB-4626-B22D-D7CB020E8F8D

Q33947287-C659FE51-D97F-4D25-ABEE-61A54B875BAB

Q33947287-C73321D6-CE9E-49E4-BA99-F6D10E2C84A1

P2860

Q33947287-00FF2C9C-FBB5-4CBF-9D22-C5943683C324

Q33947287-05C3D00E-71DE-4D34-A143-B01C423DE1D7

Q33947287-075FECE5-769A-43C8-9FE9-FDEAB69B68D9

Q33947287-0EC4D5B2-BCEC-46B2-ABF1-47F5CA1CF8C2

Q33947287-16DB3012-2E14-4114-B6DA-67C0FF3BF33E

Q33947287-187AD389-20FA-489A-BB2C-CB817CCDB2C9

Q33947287-21F8714C-B4FA-4C6F-88AF-CBD76DA7A7B4

Q33947287-3065159F-9F87-4CFA-AD1A-B89EFEFB597C

Q33947287-3171C44D-666E-4139-BC82-BE46E5037EE3

Q33947287-332D5A1C-7245-41A7-B33B-F3ACDA1E8D10

P304

Q33947287-242EC42A-59A3-468C-8999-983DD1F570BC

P31

Q33947287-19BB9914-2732-41C3-9127-DD1C0834D818

P356

Q33947287-AD3F2086-69BD-4384-BDAD-2E37D6C08168

P407

Q33947287-7D1922FA-FC71-403E-9662-1C841D63DE6D

P433

Q33947287-F2738992-F889-469E-B766-65AEA7F13208

P478

Q33947287-270D72AD-A75D-4160-AB9F-83160CA4F1D1

P577

Q33947287-56DD4CFB-E1CA-42B6-A988-22BEDE21CFAA

P5875

Q33947287-B2030A48-C560-41CC-844E-5663423BCED3

P698

Q33947287-308B117A-01F4-45BC-98EE-5492A3553FB7

P921

Q33947287-1F6E2A69-D7A6-491E-A9A2-72DA2C29DEF7

P932

Q33947287-4A3E3F8A-9047-4797-A8DB-4FF871B0BEB4

P356

AJPATH.2010.090840

P1433

The American Journal of Pathology

P1476

Suppressed accumulation of cer ...... tor subtype 2-null bone marrow

@en

P2093

Americo H Lopez-Yglesias

http://www.w3.org/2001/XMLSchema#string

Bryan R Shalloway

http://www.w3.org/2001/XMLSchema#string

C Dirk Keene

http://www.w3.org/2001/XMLSchema#string

Izabella Sokal

http://www.w3.org/2001/XMLSchema#string

Jason K Rockhill

http://www.w3.org/2001/XMLSchema#string

Kathleen S Montine

http://www.w3.org/2001/XMLSchema#string

Lisa M Keene

http://www.w3.org/2001/XMLSchema#string

Patrick J Reed

http://www.w3.org/2001/XMLSchema#string

Richard M Breyer

http://www.w3.org/2001/XMLSchema#string

Rubens C Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Neuronal oxidative damage and dendritic degeneration following activation of CD14-dependent innate immune response in vivo

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice

Transplanted bone marrow generates new neurons in human brains.

Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease.

Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis.

Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity.

The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice.

Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy.

P304

346-354

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2010.090840

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44648678

http://www.w3.org/2001/XMLSchema#string

P698

20522650

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2893677

http://www.w3.org/2001/XMLSchema#string